Compare Hut 8 Corp (HUT) vs Novavax Inc (NVAX) Price & Performance

HUT trades at $100.93, up 10.37% in the past 24 hours, with a bearish technical signal from moving averages and oscillators. The company reported a net loss of $226.15 million in 2025 despite revenue of $235.12 million, though it beat EPS estimates in two of the last three quarters. Recent news highlights its pivot to AI infrastructure, including a $4.25 billion bond issuance for data center projects (PRNewsWire, 2026-06-09).

Analyst consensus is strongly bullish with a $138.89 price target, but high valuation ratios and persistent losses pose risks. The stock's outlook hinges on successful execution of its digital infrastructure strategy, though cash flow challenges and competitive pressures remain key concerns for investors.

Novavax (NVAX) trades at $7.86, down 4.26% on the day amid a bearish technical signal, though it has beaten earnings estimates for the last three quarters. The company reported $1.12 billion in revenue for 2025 with a net income of $440.30 million, yet faces negative shareholder equity and cash flow challenges. Recent news highlights stock volatility and shareholder dissent at the AGM, while analyst consensus remains largely bullish with a $14.00 price target.

The outlook for NVAX hinges on sustaining profitability and managing cash burn, with significant upside potential per analyst targets but substantial risks from negative equity, competitive pressures, and reliance on vaccine demand. Investors must weigh the high volatility and financial health concerns against the optimistic Wall Street ratings.